ALTH Related FDA

Aug 29, 2012 06:51 AM FTC Clears Spectrum's (SPPI) Acquisition of Allos (ALTH) Acquisition

Apr 20, 2012 09:55 AM Allos (ALTH) Says CHMP Reaffirms Negative Opinion on FOLOTYN MAA

Jan 30, 2012 08:31 AM Allos Therapeutics (ALTH) Submits Request for Re-Examination of FOLOTYN Negative Opinion by CHMP

Jan 20, 2012 07:44 AM Allos Therapeutics (ALTH) Says EMA CHMP Recommends Against Approval for FOLOTYN as PTCL Treatment

Jun 20, 2011 06:36 AM Allos Therapeutics (ALTH) Updates on FOLOTYN PROPEL

Jun 17, 2011 06:51 AM Allos (ALTH) Reports Publication of Encouraging FOLOTYN Data

Jun 16, 2011 07:11 AM Allos (ALTH) Updates on COMPLETE for Futher PTCL Treatment Understanding

Jun 8, 2011 09:03 AM Allos Therapeutics (ALTH) Presents FOLOTYN Data at EHA Congress

Dec 6, 2010 09:02 AM Ariad (ARIA) May Have Been Best at ASH Meeting

Dec 6, 2010 07:34 AM Allos Therapeutics (ALTH) Presents Strong Data from PROPEL of FOLOTYN in Patients with Relapsed PTCL

Dec 6, 2010 07:31 AM Allos Therapeutics (ALTH) Announces Encouraging Data from FOLOTYN PROPEL in Patients with PTCL

Dec 1, 2010 08:08 AM Allos Therapeutics (ALTH) To Present Data for FOLOTYN Phase 2b in Patients with Stage IIIB/IV NSCLC

Nov 19, 2010 09:13 AM Allos Therapeutics (ALTH) To Present Five Abstracts of FOLOTYN Data on Blood Cancers at 52nd ASH Annual Meeting

Oct 15, 2010 09:10 AM Allos Therapeutics (ALTH) Announces the EC Grants Orphan Designation to HL Treatment Pralatrexate

Jul 28, 2010 08:31 AM Allos Therapeutics (ALTH) Announces Strong Results in FOLOTYN Phase 2b

Jun 17, 2010 09:06 AM Allos Therapeutics (ALTH) Gets Orphan Designation from EC for CTCL Treatment Pralatrexate

Jun 11, 2010 11:49 AM Allos Therapeutics (ALTH) Presents Data from FOLOTYN Phase 1

Jun 7, 2010 08:44 AM Allos Therapeutics (ALTH) Announces Strong Data Related to PROPEL Trial of FOLOTYN In Patients with PTCL

May 18, 2010 08:24 AM Allos Therapeutics (ALTH) Gets Orphan Drug Designation from U.S. FDA for Pralatrexate

Dec 7, 2009 06:52 AM Allos Thera (ALTH) Updates on Pivotal PROPEL Trail of FOLOTYN

Sep 25, 2009 10:03 AM Shares of Allos Therapeutics (ALTH) Give Back After Strong Opening

Sep 25, 2009 08:17 AM Allos Therapeutics' (ALTH) FOLOTYN First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma

Sep 23, 2009 08:20 AM Allos Therapeutics (ALTH) October volatility elevated into FDA meeting

Sep 3, 2009 08:34 AM Allos Therapeutics (ALTH) Higher Following FDA Panel Recommendation of FOLOTYN

Sep 2, 2009 04:57 PM FDA Panel Backs Allos Therapeutics (ALTH) lymphoma drug Folotyn

Aug 10, 2009 11:01 AM Allos Therapeutics (ALTH) Announces FDA Advisory Committee to Review Pralatrexate for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Jun 1, 2009 07:10 AM Allos Therapeutics (ALTH) Updates Phase 2 PROPEL Study At ASCO

May 26, 2009 08:16 AM Allos Therapeutics (ALTH) Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status

Mar 17, 2009 08:30 AM Allos Therapeutics' (ALTH) Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Bladder Cancer

Feb 4, 2009 07:02 AM Allos Therapeutics (ALTH) Announces Positive Phase 2 PROPEL Trial of Pralatrexate

Dec 8, 2008 08:56 AM Allos Therapeutics (ALTH) Reports Preliminary Top Line Results from PROPEL

Dec 1, 2008 04:06 PM Allos Therapeutics (ALTH) Granted FDA Orphan Drug Designation for Treatment of Patients with Follicular Lymphoma

Nov 24, 2008 04:41 PM Allos Therapeutics (ALTH) Announces FDA Grants Orphan Drug Status for Pralatrexate

Apr 22, 2008 08:33 AM Allos Therapeutics (ALTH) Completes Patient Enrollment in Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma

Jun 19, 2007 07:15 AM Allos Therapeutics (ALTH) Said Efaproxyn Failed to Meet Primary Endpoint

May 31, 2007 04:44 PM Allos Therapeutics (ALTH) Initiates Phase I/II Study of PDX and Gemcitabine

Dec 11, 2006 11:54 AM Allos Therapeutics (ALTH) Announces Presentation of Phase 1/2 Trials of PDX in Patients with Relapsed or Refractory non-Hodgkin's Lymphoma and Hodgkin's Disease

Dec 5, 2006 01:48 PM Needham Highlights Biotech Companies Presenting at the Upcoming American Society of Hematology

Nov 9, 2006 02:02 PM Allos Therapeutics (ALTH) Says Phase 1/2 Results of PDX to be Presented at American Society of Hematology Annual Meeting

Oct 3, 2006 08:05 AM Allos Therapeutics (ALTH) Receives FDA Fast Track Designation for PDX

Jun 28, 2006 12:34 PM Needham Analyst Discusses Partnering Opportunities in Biotech

Jun 5, 2006 08:09 AM Allos Therapeutics (ALTH) Announces Positive Pre-Clinical Study of EFAPROXYN

Apr 4, 2006 07:14 AM Allos Therapeutics (ALTH) Interim Analysis Supports Continuation of Phase 3 Trial

Mar 10, 2006 10:25 AM Needham issues a note focusing on biotech stocks with upcoming milestones in March

Feb 14, 2006 08:05 AM ALTH Said Pralatrexate Plus Gemcitabine Proves Superior to Methotrexate Plus Cytarabine

Dec 12, 2005 08:10 AM ALTH Said EFAPROXYN Extends Survival n Patients With Brain Metastases

Sep 1, 2005 08:18 AM ALTH Said EFAPROXYN May Improve Survival in Lung Cancer Patients